

# Pathway for Oral Chemo for Older Adults



Aim 1: To develop P3OC through stakeholder engagement













Aim 2: To assess the feasibility and pharmacist adoption of P3OC in a single-arm pilot study of 30 older adults prescribed OC for breast, thoracic, or hematology malignancies

Angela M. Stover, PhD and Mary-Haston Vest, PharmD, MS, BCPS


#### **P3OC Patient Interview Demographics**

Characteristic	Breast N=12	Thoracic N=12	Hematology N=12
Women	10 (83%)	6 (50%)	6 (50%)
Men	2 (17%)	6 (50%)	6 (50%)
Non-Hispanic White	4 (33%)	8 (75%)	6 (50%)
Non-Hispanic Black	4 (33%)	3 (25%)	5 (42%)
Non-Hispanic other race	4 (33%)	1 (8%)	1 (8%)
Age 65 and older	7 (58%)	8 (75%)	6 (50%)
Completed interview by zoom	5 (42%)	7 (58%)	2 (17%)
Completed interview by phone	7 (58%)	5 (42%)	10 (83%)

## Symptoms: Delphi and Interviews

Delphi	Pharmacists	Breast	Thoracic	Hematology
Felt sick to stomach	X	X	X	X
Constipation, diarrhea	X	X	X	X
Fatigue	X	X	X	X
Pain related to treatment	X	X	X	X
Mouth or throat sores	X	X	X	X
Numbness or tingling	X	X	X	
Not wanting to eat	X	X	Increased	
Dyspnea	X		X	X
Rash	X	X	X	
Sad/unhappy feelings Anxiety	X		"Mental health"	X
Usual activities		X	X	X
Trouble sleeping	X			X

### EHR Smart Form Build: 13 Symptoms



#### EHR Smart Form Build: 3 Adherence Questions

Adherence					
16. In the last 30 days, how often did you take your [drug name] as prescribed?	Never	Rarely	Sometimes	Usually	Almost Always
	Always				
15. In the last 30 days, on how many days did you miss at least one dose of any of your [drug name]?	Write in number of days, 0-30 Specify				
	chemotherapy cycle				
17. What reasons are you having trouble taking your medication [pharmacist: check all that apply]?	No	problems identifi	ed		
арріу]:	Adverse effects				
	Financial				
	Instructed by provider to hold or take differently				
	Lack of perceived benefit				
	Language barrier				
	Low health literacy				
	Paient forgets				
	К	nowledge deficit			
	Patient refuses				
	Psychosocial				
	No transportation				
	Other non-adher	ence reason (en	ter a comment)		
	Comments				
Comments:					
Optional Symptom Tracking					

#### Overview: Pilot Test Starting this Month

- Design: single arm with 20 patients per clinic (N=60)
  - Half age 65+, 40% Black, 50% women (thoracic & hematology)
- Aim 1: Acceptability and feasibility
  - o Patients: PROMs at 1 week/1 mo/3 mo, interview at 3 months
  - o Pharmacists: brief questionnaire at end of study, feedback
- Aim 2: Adoption
  - EHR data extraction:
    - Smart form PRO-CTCAE
    - Patient demographic and clinical characteristics
    - Visit characteristics/ how EHR Smart Form is used

#### Thank You to Our Stakeholder Advisory Board

Pharmacists and Leaders	Patient Advocates	PhD and MD Champions	Staff Members & Students
Debbie Liang	Kang Sung	Lorinda Coombs	Dana Mueller
Sonali Acharya	Ron Taylor	Jennifer Elston Lafata	Janiece Morgan-Glover
Jill Brese	Anne Wilson	Jennifer Lund	Dan Giang
Kaitlyn Buhlinger		Emily Miller Ray	Shweta Pathak
Kevin Chen		Gita Mody	Liang Zhao
Evan Colmenares			Christiana Ikemeh
Aimee Faso			Courtney Canter
Benyam Muluneh			
Bianca Patel			
Michael Tilkens			